Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases, announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13. The presentation will focus on the scientific basis for treating Alzheimer's disease as a multi-protein disorder and highlight Annovis' approach of simultaneously targeting multiple neurotoxic proteins through its lead drug candidate, buntanetap, which is currently in a pivotal Phase 3 clinical trial.
The presentation underscores a paradigm shift in Alzheimer's research, moving from single-target therapies toward addressing the complex interplay of toxic proteins. Buntanetap inhibits the translation of amyloid beta, tau, alpha-synuclein, and TDP-43—all implicated in neurodegeneration. By targeting these proteins simultaneously, Annovis aims to halt disease progression and improve cognitive and motor functions. This approach is particularly significant given the recent failures of monoclonal antibodies targeting only amyloid beta, which have shown limited clinical benefit and safety concerns.
Annovis' Phase 3 trial evaluates buntanetap's efficacy in early Alzheimer's patients, measuring cognitive and functional outcomes. If successful, buntanetap could become a foundational treatment for Alzheimer's and potentially other neurodegenerative diseases like Parkinson's. The company's strategy aligns with growing evidence that Alzheimer's involves multiple pathological proteins, and that effective therapies must address this complexity.
For more details, the full press release is available at https://ibn.fm/kZ2Z4. Annovis Bio is headquartered in Malvern, Pennsylvania, and additional information can be found at www.annovisbio.com.
